ICP-022
ICP-CL-00109
Phase 2 small_molecule completed
Quick answer
ICP-022 for Systemic Lupus Erythematosus is a Phase 2 program (small_molecule) at Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
- Indication
- Systemic Lupus Erythematosus
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed